Illumina acquires Fluent BioSciences | LabPulse.com

Illumina announced the acquisition of Fluent BioSciences, a company developing single-cell analysis technology.

In a statement, Illumina said the acquisition closed on Tuesday, June 9, and was funded with cash. Additional financial details of the acquisition were not disclosed.

The Fluent team will join Illumina. Illumina will remain an open next-generation sequencing platform; the company said it is “committed to maintaining and supporting existing single-cell partnerships.”

Fluent’s PIPseq V technology will be integrated into Illumina’s product portfolio. The company plans to expand Fluent’s technology to include comprehensive end-to-end solutions for single-cell analysis.

“The addition of Fluent BioSciences to Illumina will provide significant new capabilities to our customers in a key growth area and advance our multi-omics development strategy,” said Steven Barnard, chief technology officer at Illumina.

“Single-cell research opens the door to new areas of discovery, and Fluent’s innovative, accessible and flexible single-cell approach will accelerate our ability to deliver complete multi-omics solutions to our customers.”